|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Scott_Wolchko
|
|
gptkbp:collaboratedWith
|
gptkb:Janssen_Biotech
gptkb:ONK_Therapeutics
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:developedBy
|
off-the-shelf NK cell therapies
off-the-shelf T cell therapies
|
|
gptkbp:focusesOn
|
gptkb:cancer
immunotherapy
gene therapy
hematologic malignancies
|
|
gptkbp:foundedYear
|
2007
|
|
gptkbp:founder
|
gptkb:John_D._Mendlein
gptkb:Rafael_Amado
gptkb:Scott_Wolchko
|
|
gptkbp:headquartersLocation
|
gptkb:San_Diego,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fate Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:notableProduct
|
gptkb:FT516
gptkb:FT538
gptkb:FT596
gptkb:FT819
|
|
gptkbp:numberOfEmployees
|
approximately 400 (as of 2023)
|
|
gptkbp:stockSymbol
|
gptkb:FATE
|
|
gptkbp:technology
|
iPSC (induced pluripotent stem cell) platform
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:FATE
|
|
gptkbp:website
|
https://fatetherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:Arch_Venture_Partners
|
|
gptkbp:bfsLayer
|
6
|